Published in Infect Immun on July 01, 2006
Spatial localization of bacteria controls coagulation of human blood by 'quorum acting'. Nat Chem Biol (2008) 1.74
Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome. Infect Immun (2007) 1.28
Candidate antigens for Q fever serodiagnosis revealed by immunoscreening of a Coxiella burnetii protein microarray. Clin Vaccine Immunol (2008) 1.22
The adenylyl cyclase activity of anthrax edema factor. Mol Aspects Med (2009) 1.15
Plasmodium immunomics. Int J Parasitol (2010) 1.09
Immunospecific responses to bacterial elongation factor Tu during Burkholderia infection and immunization. PLoS One (2010) 1.08
Bacillus anthracis peptidoglycan stimulates an inflammatory response in monocytes through the p38 mitogen-activated protein kinase pathway. PLoS One (2008) 1.07
Mining the Moraxella catarrhalis genome: identification of potential vaccine antigens expressed during human infection. Infect Immun (2008) 1.06
Differential contribution of Bacillus anthracis toxins to pathogenicity in two animal models. Infect Immun (2012) 0.96
Application of in vivo induced antigen technology (IVIAT) to Bacillus anthracis. PLoS One (2008) 0.93
Pumping iron: a potential target for novel therapeutics against schistosomes. Trends Parasitol (2007) 0.93
Penetration of the blood-brain barrier by Bacillus anthracis requires the pXO1-encoded BslA protein. J Bacteriol (2009) 0.91
Hal Is a Bacillus anthracis heme acquisition protein. J Bacteriol (2012) 0.88
Identification of the immunogenic spore and vegetative proteins of Bacillus anthracis vaccine strain A16R. PLoS One (2013) 0.84
Genetic analysis of petrobactin transport in Bacillus anthracis. Mol Microbiol (2010) 0.83
Investigating the genome diversity of B. cereus and evolutionary aspects of B. anthracis emergence. Genomics (2011) 0.83
Novel and unique diagnostic biomarkers for Bacillus anthracis infection. Appl Environ Microbiol (2009) 0.80
Effect of Bacillus anthracis virulence factors on human dendritic cell activation. Hum Immunol (2008) 0.79
Immunization of mice with formalin-inactivated spores from avirulent Bacillus cereus strains provides significant protection from challenge with Bacillus anthracis Ames. Clin Vaccine Immunol (2012) 0.78
An update on the transport and metabolism of iron in Listeria monocytogenes: the role of proteins involved in pathogenicity. Biometals (2015) 0.78
Next-Generation Bacillus anthracis Live Attenuated Spore Vaccine Based on the htrA(-) (High Temperature Requirement A) Sterne Strain. Sci Rep (2016) 0.77
Changes in Bacillus anthracis CodY regulation under host-specific environmental factor deprived conditions. BMC Genomics (2016) 0.75
Identification of novel and cross-species seroreactive proteins from Bacillus anthracis using a ligation-independent cloning-based, SOS-inducible expression system. Microb Pathog (2012) 0.75
Progress toward the Development of a NEAT Protein Vaccine for Anthrax Disease. Infect Immun (2016) 0.75
The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. Nature (2003) 10.38
Iron metabolism in pathogenic bacteria. Annu Rev Microbiol (2000) 7.91
Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev (1999) 7.76
Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (2000) 7.41
Passage of heme-iron across the envelope of Staphylococcus aureus. Science (2003) 4.83
Iron and microbial infection. Nat Rev Microbiol (2004) 4.53
Sequence and organization of pXO1, the large Bacillus anthracis plasmid harboring the anthrax toxin genes. J Bacteriol (1999) 4.50
Iron-source preference of Staphylococcus aureus infections. Science (2004) 4.33
A proteomic view on genome-based signal peptide predictions. Genome Res (2001) 3.96
Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science (2005) 3.83
Protein repeats: structures, functions, and evolution. J Struct Biol (2001) 3.67
A collagen-like surface glycoprotein is a structural component of the Bacillus anthracis exosporium. Mol Microbiol (2002) 3.26
Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev (2001) 3.25
Autolysins of Bacillus subtilis: multiple enzymes with multiple functions. Microbiology (2000) 3.18
Evolutionary history, structural features and biochemical diversity of the NlpC/P60 superfamily of enzymes. Genome Biol (2003) 3.02
Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun (1986) 2.94
Bacteriophage endolysins--current state of research and applications. Curr Opin Microbiol (2005) 2.85
Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun (2001) 2.68
Bacterial SLH domain proteins are non-covalently anchored to the cell surface via a conserved mechanism involving wall polysaccharide pyruvylation. EMBO J (2000) 2.66
Protein sorting to the cell wall envelope of Gram-positive bacteria. Biochim Biophys Acta (2004) 2.42
Cell wall attachment of a widely distributed peptidoglycan binding domain is hindered by cell wall constituents. J Biol Chem (2003) 2.28
Surface proteins and the pathogenic potential of Listeria monocytogenes. Trends Microbiol (2002) 2.24
SecA2-dependent secretion of autolytic enzymes promotes Listeria monocytogenes pathogenesis. Proc Natl Acad Sci U S A (2003) 2.18
Bacillus anthracis requires siderophore biosynthesis for growth in macrophages and mouse virulence. Mol Microbiol (2004) 2.12
Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect Immun (2003) 2.05
Pattern searches for the identification of putative lipoprotein genes in Gram-positive bacterial genomes. Microbiology (2002) 1.98
Molecular characterization of the Bacillus anthracis main S-layer component: evidence that it is the major cell-associated antigen. Mol Microbiol (1997) 1.96
Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun (2002) 1.94
Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun (2000) 1.93
Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc Natl Acad Sci U S A (2003) 1.87
Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect Immun (1995) 1.81
Anthrax toxins and the host: a story of intimacy. Cell Microbiol (2003) 1.75
Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect Immun (1990) 1.72
NEAT: a domain duplicated in genes near the components of a putative Fe3+ siderophore transporter from Gram-positive pathogenic bacteria. Genome Biol (2002) 1.72
Genomic analysis of secretion systems. Curr Opin Microbiol (2003) 1.68
Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun (2002) 1.64
The InhA2 metalloprotease of Bacillus thuringiensis strain 407 is required for pathogenicity in insects infected via the oral route. J Bacteriol (2002) 1.64
A family of putative MSCRAMMs from Enterococcus faecalis. Microbiology (2004) 1.63
Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun (2002) 1.62
Anchorless adhesins and invasins of Gram-positive bacteria: a new class of virulence factors. Trends Microbiol (2002) 1.61
Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis. Infect Immun (1986) 1.57
Structure and function of anthrax toxin. Curr Top Microbiol Immunol (2002) 1.56
A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc Natl Acad Sci U S A (2003) 1.54
Iron acquisition by Gram-positive bacterial pathogens. Microbes Infect (2002) 1.52
Characterization of the exosporium of Bacillus cereus. J Appl Microbiol (1999) 1.51
Cell wall-targeting domain of glycylglycine endopeptidase distinguishes among peptidoglycan cross-bridges. J Biol Chem (2005) 1.48
Bacillus anthracis sortase A (SrtA) anchors LPXTG motif-containing surface proteins to the cell wall envelope. J Bacteriol (2005) 1.46
The multifunctional Staphylococcus aureus autolysin aaa mediates adherence to immobilized fibrinogen and fibronectin. Infect Immun (2005) 1.43
The ExPortal: an organelle dedicated to the biogenesis of secreted proteins in Streptococcus pyogenes. Mol Microbiol (2005) 1.41
Role of HtrA in the virulence and competence of Streptococcus pneumoniae. Infect Immun (2004) 1.40
Virulence potential of the staphylococcal adhesin CNA in experimental arthritis is determined by its affinity for collagen. J Infect Dis (2004) 1.36
Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect Immun (2006) 1.35
Anthrax vaccines. Curr Top Microbiol Immunol (2002) 1.35
DNA sequence conservation between the Bacillus anthracis pXO2 plasmid and genomic sequence from closely related bacteria. BMC Genomics (2002) 1.34
Auto, a surface associated autolysin of Listeria monocytogenes required for entry into eukaryotic cells and virulence. Mol Microbiol (2004) 1.32
Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect Immun (2002) 1.31
A plasmid-encoded regulator couples the synthesis of toxins and surface structures in Bacillus anthracis. Mol Microbiol (2003) 1.30
Differential proteomic analysis of the Bacillus anthracis secretome: distinct plasmid and chromosome CO2-dependent cross talk mechanisms modulate extracellular proteolytic activities. J Bacteriol (2006) 1.28
Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen. Infect Immun (1999) 1.26
Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening. Infect Immun (2002) 1.26
Bacillus anthracis, a bug with attitude! Curr Opin Microbiol (2001) 1.22
Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev (2002) 1.22
Evidence for contribution of tripartite hemolysin BL, phosphatidylcholine-preferring phospholipase C, and collagenase to virulence of Bacillus cereus endophthalmitis. Infect Immun (2000) 1.21
Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine (2001) 1.19
The extracellular proteome of Bacillus subtilis under secretion stress conditions. Mol Microbiol (2003) 1.18
Identification of the Bacillus anthracis (gamma) phage receptor. J Bacteriol (2005) 1.17
Identification and biochemical characterization of two novel collagen binding MSCRAMMs of Bacillus anthracis. J Biol Chem (2004) 1.13
Evidence for two immune inhibitors from Bacillus thuringiensis interfering with the humoral defense system of saturniid pupae. Infect Immun (1976) 1.12
Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens. Infect Immun (2003) 1.11
Prevalence of cna, fnbA and fnbB adhesin genes among Staphylococcus aureus isolates from orthopedic infections associated to different types of implant. FEMS Microbiol Lett (2005) 1.10
The Haemophilus influenzae HtrA protein is a protective antigen. Infect Immun (1998) 1.08
The InhA1 metalloprotease allows spores of the B. cereus group to escape macrophages. Cell Microbiol (2005) 1.08
The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant. Mol Microbiol (2005) 1.08
Virulence factors in Bacillus thuringiensis: purification and properties of a protein inhibitor of immunity in insects. J Gen Microbiol (1979) 1.07
Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infect Immun (2003) 1.06
A framework for interpreting the leucine-rich repeats of the Listeria internalins. Proc Natl Acad Sci U S A (2000) 1.05
Characterization of an extracellular virulence factor made by group A Streptococcus with homology to the Listeria monocytogenes internalin family of proteins. Infect Immun (2003) 1.05
Importance of srtA and srtB for growth of Bacillus anthracis in macrophages. Infect Immun (2005) 1.03
Plasmid-encoded autolysin in Bacillus anthracis: modular structure and catalytic properties. J Bacteriol (2002) 1.02
Identification of new potential vaccine candidates against Chlamydia pneumoniae by multiple screenings. Vaccine (2005) 1.02
Genome-derived vaccines. Expert Rev Vaccines (2004) 1.01
Production of Bacillus anthracis protective antigen is dependent on the extracellular chaperone, PrsA. J Biol Chem (2003) 1.00
Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccines. Infect Immun (2003) 1.00
Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation. Infect Immun (2005) 0.97
Regulation of htrA expression in Yersinia enterocolitica. FEMS Microbiol Lett (2004) 0.95
Identification of chromosomally encoded membranal polypeptides of Bacillus anthracis by a proteomic analysis: prevalence of proteins containing S-layer homology domains. Proteomics (2004) 0.94
Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun (2005) 0.93
Two years into reverse vaccinology. Vaccine (2003) 0.92
Brucella abortus HtrA functions as an authentic stress response protease but is not required for wild-type virulence in BALB/c mice. Infect Immun (2001) 0.91
Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Vaccine (2005) 0.87
Application of microbial genomic science to advanced therapeutics. Annu Rev Med (2005) 0.86
Implications of physiological studies based on genomic sequences: Streptococcus pneumoniae TIGR4 synthesizes a functional LytC lysozyme. J Bacteriol (2005) 0.79
In vitro screen of bioinformatically selected Bacillus anthracis vaccine candidates by coupled transcription, translation, and immunoprecipitation analysis. Methods Mol Biol (2007) 0.79
Comparison of sequence and structure alignments for protein domains. Proteins (2002) 4.24
Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization. Clin Vaccine Immunol (2009) 2.00
Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun (2002) 1.64
Acupuncture in the treatment of upper-limb lymphedema: results of a pilot study. Cancer (2013) 1.62
Protective antigen as a correlative marker for anthrax in animal models. Infect Immun (2006) 1.43
Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect Immun (2006) 1.35
Biochemical characterization and identification of the catalytic residues of a family 43 beta-D-xylosidase from Geobacillus stearothermophilus T-6. Biochemistry (2005) 1.29
Differential proteomic analysis of the Bacillus anthracis secretome: distinct plasmid and chromosome CO2-dependent cross talk mechanisms modulate extracellular proteolytic activities. J Bacteriol (2006) 1.28
A two-component system regulates the expression of an ABC transporter for xylo-oligosaccharides in Geobacillus stearothermophilus. Appl Environ Microbiol (2006) 1.28
Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome. Infect Immun (2007) 1.28
Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates. Infect Immun (2004) 1.26
Interrelationship between dendritic cell trafficking and Francisella tularensis dissemination following airway infection. PLoS Pathog (2008) 1.25
Progress and novel strategies in vaccine development and treatment of anthrax. Immunol Rev (2011) 1.19
Interaction of Yersinia pestis with macrophages: limitations in YopJ-dependent apoptosis. Infect Immun (2006) 1.17
Identification of strain specific markers in Bacillus anthracis by random amplification of polymorphic DNA. FEMS Microbiol Lett (2005) 1.17
Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infect Immun (2004) 1.16
The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis. PLoS One (2010) 1.16
Construction of a rhamnose mutation in Bacillus anthracis affects adherence to macrophages but not virulence in guinea pigs. Microb Pathog (2005) 1.15
Crystal structures of Geobacillus stearothermophilus alpha-glucuronidase complexed with its substrate and products: mechanistic implications. J Biol Chem (2003) 1.12
Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Med Genomics (2008) 1.10
The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant. Mol Microbiol (2005) 1.08
Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague. PLoS One (2009) 1.07
Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infect Immun (2003) 1.06
Development of an improved selective agar medium for isolation of Yersinia pestis. Appl Environ Microbiol (2003) 1.02
Characterization of Bacillus anthracis iron-regulated surface determinant (Isd) proteins containing NEAT domains. Mol Microbiol (2008) 1.02
The NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the development of plague. PLoS One (2009) 1.01
Comparison of polyethylene glycol-conjugated recombinant human acetylcholinesterase and serum human butyrylcholinesterase as bioscavengers of organophosphate compounds. Mol Pharmacol (2006) 1.01
Antibiotics cure anthrax in animal models. Antimicrob Agents Chemother (2011) 1.00
Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains. Vaccine (2003) 0.99
Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. J Infect Dis (2009) 0.97
Acute hyperglycemia worsens hepatic ischemia/reperfusion injury in rats. J Gastrointest Surg (2009) 0.96
Differential contribution of Bacillus anthracis toxins to pathogenicity in two animal models. Infect Immun (2012) 0.96
Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague. Vaccine (2008) 0.95
HtrA is a major virulence determinant of Bacillus anthracis. Mol Microbiol (2011) 0.95
Identification of chromosomally encoded membranal polypeptides of Bacillus anthracis by a proteomic analysis: prevalence of proteins containing S-layer homology domains. Proteomics (2004) 0.94
Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response. Vaccine (2009) 0.92
The NheA component of the non-hemolytic enterotoxin of Bacillus cereus is produced by Bacillus anthracis but is not required for virulence. Microb Pathog (2004) 0.91
Discordance in the effects of Yersinia pestis on the dendritic cell functions manifested by induction of maturation and paralysis of migration. Infect Immun (2006) 0.91
Clinical and immune responses after revaccination of israeli adults with the Lister strain of vaccinia virus. J Infect Dis (2004) 0.91
Impact of the "polytrauma clinical triad" on sleep disturbance in a department of veterans affairs outpatient rehabilitation setting. Am J Phys Med Rehabil (2010) 0.90
Factors associated with Trypanosoma cruzi exposure among domestic canines in Tennessee. J Parasitol (2010) 0.89
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem (2006) 0.88
Proteomic studies of Bacillus anthracis. Future Microbiol (2009) 0.87
Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen. J Biol Chem (2005) 0.87
Lethal factor is not required for Bacillus anthracis virulence in guinea pigs and rabbits. Microb Pathog (2011) 0.87
The effect of deletion of the edema factor on Bacillus anthracis pathogenicity in guinea pigs and rabbits. Microb Pathog (2011) 0.86
Use of ventricular assist devices in patients with mitral valve prostheses. J Card Surg (2011) 0.86
Expression, purification, and isotope labeling of the Fv of the human HIV-1 neutralizing antibody 447-52D for NMR studies. Protein Expr Purif (2003) 0.85
T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague. Vaccine (2011) 0.85
A safety and efficacy pilot study of acupuncture for the treatment of chronic lymphoedema. Acupunct Med (2011) 0.85
Identification and characterization of novel and potent transcription promoters of Francisella tularensis. Appl Environ Microbiol (2010) 0.85
Disparity between Yersinia pestis and Yersinia enterocolitica O:8 in YopJ/YopP-dependent functions. Adv Exp Med Biol (2007) 0.84
Whole-genome immunoinformatic analysis of F. tularensis: predicted CTL epitopes clustered in hotspots are prone to elicit a T-cell response. PLoS One (2011) 0.83
Enrichment of Yersinia pestis from blood cultures enables rapid antimicrobial susceptibility determination by flow cytometry. Adv Exp Med Biol (2007) 0.83
Stereoselectivity toward VX is determined by interactions with residues of the acyl pocket as well as of the peripheral anionic site of AChE. Biochemistry (2004) 0.83
Controlled concealment of exposed clearance and immunogenic domains by site-specific polyethylene glycol attachment to acetylcholinesterase hypolysine mutants. J Biol Chem (2007) 0.83
Evaluation of protective immunity induced by Yersinia enterocolitica type-III secretion system mutants. Adv Exp Med Biol (2003) 0.83
Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection. Antimicrob Agents Chemother (2012) 0.82
The aromatic "trapping" of the catalytic histidine is essential for efficient catalysis in acetylcholinesterase. Biochemistry (2002) 0.82
The search for early markers of plague: evidence for accumulation of soluble Yersinia pestis LcrV in bubonic and pneumonic mouse models of disease. FEMS Immunol Med Microbiol (2010) 0.82
Aging-resistant organophosphate bioscavenger based on polyethylene glycol-conjugated F338A human acetylcholinesterase. Mol Pharmacol (2008) 0.82
A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion. J Biol Chem (2012) 0.81
Early sensing of Yersinia pestis airway infection by bone marrow cells. Front Cell Infect Microbiol (2012) 0.80
Novel and unique diagnostic biomarkers for Bacillus anthracis infection. Appl Environ Microbiol (2009) 0.80